Lisinopril Dosing Guidelines

Dosing Considerations

For heart failure, the recommended starting dose is 5mg once daily, which can be titrated up to a maximum of 40mg once daily, as recommended by the American Heart Association 1
For heart failure with reduced ejection fraction (HFrEF), the target dose of lisinopril is 20mg once daily, according to the American College of Cardiology 2, 3
At least 50% of the target dose (10mg daily) should be achieved for optimal clinical benefit in heart failure patients, as suggested by the American College of Cardiology 2, 3

When titrating, increase the dose at intervals of not less than 2 weeks, as recommended by the European Society of Cardiology 4, 5, 3
Aim for target dose or, if not tolerated, the highest tolerated dose, according to the European Society of Cardiology 4, 5
Monitor blood chemistry (urea, creatinine, potassium) and blood pressure during initiation and dose adjustments, as suggested by the European Society of Cardiology 4, 5
An increase in creatinine of up to 50% above baseline is acceptable when initiating therapy, as stated by the European Society of Cardiology 6

Initial doses may cause symptomatic hypotension, particularly in volume-depleted patients or those on diuretics, as warned by the American Heart Association 1
Monitor potassium levels, especially when combined with potassium-sparing diuretics or supplements, as recommended by the European Society of Cardiology and the American Heart Association 4, 1
ACE inhibitor-induced cough is common (up to 20% of patients) but rarely requires discontinuation, as reported by the American Heart Association 1
Angioedema is a potentially life-threatening reaction that warrants permanent discontinuation of all ACE inhibitors, as warned by the American Heart Association and the American College of Cardiology 1, 7

The European Society of Cardiology recommends aiming for a target dose of 30-35 mg once daily in heart failure patients, as higher doses provide superior outcomes, including a 12% lower risk of death or hospitalization and 24% fewer heart failure hospitalizations 8, 9
Titration of doses should be done at intervals of not less than 2 weeks, monitoring blood pressure, renal function, and potassium, to ensure clinical benefit in heart failure patients, with a goal of at least 50% of the target dose 8, 9

The European Society of Cardiology suggests that some ACE inhibitor is better than no ACE inhibitor, and to use the highest tolerated dose even if the target cannot be reached, as demonstrated by the ATLAS trial 8, 9

An increase in creatinine up to 50% above baseline is acceptable when initiating or uptitrating therapy, according to the European Society of Cardiology guidelines 8, 9
Asymptomatic hypotension does not require dose reduction, but if symptomatic hypotension occurs, consideration should be given to reducing diuretic dose before lowering lisinopril dose, as recommended by the European Society of Cardiology 8, 9

The American College of Cardiology recommends starting lisinopril at 2.5-5 mg once daily and titrating to a target dose of 20-40 mg once daily for heart failure with reduced ejection fraction, with higher doses demonstrating superior mortality reduction compared to lower doses 10, 11

The American College of Cardiology suggests targeting the highest tolerated dose of lisinopril, as mortality benefit is dose-dependent, with the ATLAS trial demonstrating that high-dose lisinopril (32.5-35 mg daily) reduced mortality significantly more than low-dose (2.5-5 mg daily) 10, 11, 12, 13

The American Heart Association recommends avoiding combination therapy with ARBs in acute settings, such as post-myocardial infarction, due to increased adverse effects without added benefit, though combination may be beneficial in stable chronic heart failure 11, 12, 13

The European Society of Cardiology recommends a target dose of 20-35 mg once daily for optimal mortality benefit in patients with heart failure with reduced ejection fraction, with high-dose lisinopril (32.5-35 mg daily) reducing death or hospitalization by 12% and heart failure hospitalizations by 24% 14
The European Heart Journal suggests monitoring blood pressure, serum creatinine, and potassium within 5-7 days after initiation or dose increases, and continuing monitoring at 3 months, then every 6 months during maintenance therapy 14

The European Heart Journal recommends checking blood pressure, serum creatinine, and potassium within 5-7 days after initiation or dose increases, and continuing monitoring at 3 months, then every 6 months during maintenance therapy 14

The 2017 ACC/AHA hypertension guideline recommends initiating two‑drug therapy (including lisinopril) in patients with stage 2 hypertension—defined as blood pressure ≥20/10 mm Hg above target—either as separate agents or as a fixed‑dose combination. 15

The ACC advises exercising caution when starting combination antihypertensive therapy (e.g., lisinopril plus another agent) in older adults (≥65 years) because of a higher risk of symptomatic and orthostatic hypotension; close blood‑pressure monitoring is recommended. 15
The ACC also supports a stepped‑care approach for elderly patients at risk of hypotension, favoring initiation with a single agent (such as lisinopril) and sequential dose titration before adding additional drugs. 15